Edition:
United Kingdom

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

7.93USD
21 Feb 2018
Change (% chg)

$0.34 (+4.48%)
Prev Close
$7.59
Open
$7.60
Day's High
$8.19
Day's Low
$7.60
Volume
112,538
Avg. Vol
328,508
52-wk High
$15.01
52-wk Low
$4.10

Chart for

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $644.09
Shares Outstanding(Mil.): 72.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

Maryland sues Insys to enforce subpoena in opioid probe

Maryland's attorney general has filed a lawsuit seeking to enforce a subpoena the state sent Insys Therapeutics Inc as part of a probe into allegations the drugmaker deceptively marketed a fentanyl-based cancer pain medicine.

09 Feb 2018

Maryland sues Insys to enforce subpoena in opioid probe

Feb 8 Maryland's attorney general has filed a lawsuit seeking to enforce a subpoena the state sent Insys Therapeutics Inc as part of an investigation into allegations the drugmaker deceptively marketed a fentanyl-based cancer pain medicine.

08 Feb 2018

MARYLAND FILES LAWSUIT TO ENFORCE SUBPOENA AGAINST INSYS THERAPEUTICS INC IN OPIOID PROBE - COURT PAPERS

MARYLAND FILES LAWSUIT TO ENFORCE SUBPOENA AGAINST INSYS THERAPEUTICS INC IN OPIOID PROBE - COURT PAPERS

08 Feb 2018

New York accuses Insys of deceptively marketing opioid

Insys Therapeutics Inc's legal woes deepened on Thursday as New York's attorney general filed a lawsuit seeking at least $75 million from the company, which he said deceptively promoted a fentanyl-based cancer pain medicine for unsafe uses.

02 Feb 2018

UPDATE 2-New York accuses Insys of deceptively marketing opioid

Feb 1 Insys Therapeutics Inc's legal woes deepened on Thursday as New York's attorney general filed a lawsuit seeking at least $75 million from the company, which he said deceptively promoted a fentanyl-based cancer pain medicine for unsafe uses.

02 Feb 2018

New York accuses Insys of deceptively marketing opioid

Feb 1 New York's attorney general on Thursday filed a lawsuit against Insys Therapeutics Inc seeking $75 million from the pharmaceutical company, which he said deceptively promoted a powerful fentanyl-based cancer pain medicine for unsafe uses.

01 Feb 2018

Ex-Insys employee seeks ban on mentioning 'opioid crisis' at trial

A former Insys Therapeutics Inc employee accused of engaging in a scheme to pay medical practitioners kickbacks to prescribe a fentanyl-based treatment is seeking to bar U.S. prosecutors from referring to the "opioid crisis" at his trial.

11 Jan 2018

Ex-Insys employee seeks ban on mentioning 'opioid crisis' at trial

Jan 11 A former Insys Therapeutics Inc employee accused of engaging in a scheme to pay medical practitioners kickbacks to prescribe a fentanyl-based treatment is seeking to bar U.S. prosecutors from referring to the "opioid crisis" at his trial.

11 Jan 2018

BRIEF-Insys' Treatment For Prader-Willi Syndrome Gets ‘Fast Track’ Designation

* FDA GRANTS INSYS THERAPEUTICS ‘FAST TRACK’ DESIGNATION FOR CANNABIDIOL (CBD) ORAL SOLUTION AS INVESTIGATIONAL TREATMENT FOR PRADER-WILLI SYNDROME

26 Dec 2017

North Carolina accuses drugmaker Insys of scheme to push opioid

BOSTON North Carolina sued Insys Therapeutics Inc on Thursday, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys to boost profits amid the U.S. opioid epidemic.

21 Dec 2017

Earnings vs. Estimates